Regen BioPharma Inc

Regen BioPharma Inc. reported a net profit of $991,927 for the quarter ended March 31, 2026, a significant improvement from a net loss of $19,354 in the prior year quarter, primarily driven by derivative income. For the six months, the company posted a net profit of $24,074, compared to a loss of $534,739 in the previous year. However, the company's cash balance plummeted to $271, and it continues to face substantial doubt about its ability to continue as a going concern due to accumulated deficits and ongoing operational losses.